We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
-19.28%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$85.9M
AUM Growth
-$17.7M
Cap. Flow
+$10.3M
Cap. Flow %
11.97%
Top 10 Hldgs %
58.4%
Holding
67
New
17
Increased
15
Reduced
14
Closed
19

Top Buys

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$5.49M
2
HARP
Harpoon Therapeutics, Inc. Common Stock
HARP
+$4.89M
3
ZYXI
Zynex
ZYXI
+$3.73M
4
ATRS
Antares Pharma, Inc.
ATRS
+$2.94M
5
VCEL icon
Vericel Corp
VCEL
+$2.53M

Top Sells

Rank Stock Value
1
WMGI
Wright Medical Group Inc
WMGI
+$6.91M
2
AGN
Allergan plc
AGN
+$2.62M
3
DERM
Dermira, Inc.
DERM
+$2.5M
4
HUM icon
Humana
HUM
+$2.13M
5
BPMC
Blueprint Medicines
BPMC
+$2.11M

Sector Composition

Rank Sector Weight
1 Healthcare 97.9%
2 Real Estate 1.33%
3 Communication Services 0.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ESPR
51
DELISTED
Esperion Therapeutics
ESPR
– –
-6,700
Closed -$399K
FATE icon
52
Fate Therapeutics
FATE
$326M
– –
-11,400
Closed -$223K
GH icon
53
Guardant Health
GH
$22.6B
– –
-4,900
Closed -$382K
HUM icon
54
Humana
HUM
$46.2B
– –
-5,800
Closed -$2.13M
ICAD
55
DELISTED
iCAD Inc
ICAD
– –
-94,900
Closed -$737K
INSP icon
56
Inspire Medical Systems
INSP
$1.74B
– –
-9,008
Closed -$668K
NTRA icon
57
Natera
NTRA
$46.4B
– –
-13,000
Closed -$437K
STE icon
58
Steris
STE
$23.1B
– –
-8,800
Closed -$1.34M
TNDM icon
59
Tandem Diabetes Care
TNDM
$1.56B
– –
-7,600
Closed -$453K
NVRO
60
DELISTED
NEVRO CORP.
NVRO
– –
-8,246
Closed -$969K
ZEAL
61
DELISTED
Zealand Pharma A/S American Depositary Shares
ZEAL
– –
-26,882
Closed -$892K
ARNA
62
DELISTED
Arena Pharmaceuticals Inc
ARNA
– –
-11,100
Closed -$504K
DRNA
63
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
– –
-10,700
Closed -$235K
FLXN
64
DELISTED
Flexion Therapeutics, Inc.
FLXN
– –
-34,900
Closed -$722K
WMGI
65
DELISTED
Wright Medical Group Inc
WMGI
– –
-226,700
Closed -$6.91M
DERM
66
DELISTED
Dermira, Inc.
DERM
– –
-164,600
Closed -$2.5M
1 2
3

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return
SIM
Stratos Investment Management Beachwood, Ohio $2.49B AUM 17.24% 1-Year Est. Return
QT
Quantbot Technologies New York $2.44B AUM 17.13% 1-Year Est. Return

Soleus Capital Management's Q1 2020 Portfolio in Review

As of Q1 2020, Soleus Capital Management held 67 positions worth $85.9M, down 17% from $104M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Soleus Capital Management deployed $10.3M of net new capital in Q1 2020, opening 17 new positions and adding to 15 existing holdings. Its largest new stake was Zynex: 383,420 shares worth $3.86M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 96% a quarter earlier, followed by Real Estate and Communication Services.

On the sell side, the largest reduction was Allergan plc, an estimated $2.62M trimmed.

  • Soleus Capital Management's largest Q1 2020 buy was Zynex: 383,420 shares worth $3.86M.
  • Soleus Capital Management added most to IVERIC bio, Inc. Common Stock in Q1 2020, an estimated $5.49M increase.
  • Soleus Capital Management's biggest Q1 2020 reduction was Allergan plc, cutting an estimated $2.62M.
  • Soleus Capital Management fully exited Wright Medical Group Inc in Q1 2020, selling an estimated $6.91M.
  • Soleus Capital Management's ten largest holdings make up 58% of its $85.9M portfolio in Q1 2020.
  • Soleus Capital Management opened 17 new positions and closed 19 in Q1 2020.
  • Soleus Capital Management's portfolio value fell 17% quarter-over-quarter to $85.9M.

Based on Soleus Capital Management's 13F filing for Q1 2020, filed 15 May 2020.